Monthly Archives: June, 2010
ADVENTRX Announces 9-Month Stability Data Results for ANX-530
ADVENTRX Pharmaceuticals, Inc. Amex: ANX today announced the results of stability tests performed on samples of ANX-530 (vinorelbine injectable emulsion), or Exelbine(TM), manufactured at the Company’s intended commercial manufacturing site. The 9-month stability data are on track to support the submission of a New Drug Application (NDA) for Exelbine. “These results are consistent with our [...]
VVUS :NASDAQ Added to our watch list
The next few weeks could start to get very interesting we have Vivus VVUS :NASDAQ coming up for the FDA panel meeting on the 15th of July. Qnexa could be the new miracle weight loss drug that we have all been waiting for if the FDA give it the thumbs up, pennystocpicksus.com are looking for [...]
ANX Shareholder Meeting 30th June
The shareholder meeting for Adventrx Pharmaceuticals, Inc ANX : (AMEX) is on the the 30th of June, last trade $1.85 could see a little run into the meeting, keep this on your watch list for the next few days.
The Pink Sheets
Pink sheet stocks are a whole different ball game in the markets where one can lose or make money very quickly, you will mainly lose with the pinks as it can be like a lawless town in mid west in the 1800s. The Pink Sheets is not a stock exchange. As such, it can list [...]
ACAD featured Phase 3 play
We have added ACADIA Pharmaceuticals Inc. (ACAD): Nasdaq to our featured and our watch list today and ask you to do some research on this company. We just love the pharma tech plays specially the smaller ones as they could have potential for big moves. ACADIA Pharmaceuticals Inc. (ACAD) : Nasdaq ) Currently trading on [...]
AEZS Announces $12 Million in Registered Direct Offering
Aeterna Zentaris Inc. (NASDAQ: AEZS) announced today that it has received commitments from institutional investors to purchase US$12.1 million of securities in a registered direct offering. Under the terms of a Securities Purchase Agreement, the Company will sell to such institutional investors an aggregate of approximately 8.8 million common shares of its capital at a [...]
FDA Lift Clinical Hold on RPRX
FDA Lifts Full Clinical Hold on Repros’ Proellex(R) Company allowed to conduct low dose study to determine whether a safe and potentially effective dose of Proellex can be developed THE WOODLANDS, Texas, Jun 11, 2010 (BUSINESS WIRE) — Repros Therapeutics Inc. (NasdaqCM:RPRX) today announced it has received written confirmation from the FDA noting the full [...]
Avanir Pharmaceuticals, AVNR Upgrade to a buy
AVNR upgraded to a buy with a price target of $8.00, Cantor Fitzgerald Initiates Coverage on Avanir Pharmaceuticals with a buy, Avanir Pharmaceuticals, Inc. ANVR is a pharmaceutical company focused on acquiring, developing and commercializing therapeutic products for the treatment of central nervous system disorders. Shares trading up 23 cents, Shares closed @ $2.22 yesterday.
Site Problems
We are very sorry for the slow page loadings the last few weeks, Problems are now resolved thank you.
Arena Pharmaceuticals, Inc. ARNA : Nasdaq
ARNA could start to become quite interesting play on the run up to the NDA, The FDA has notified the company of the tentative scheduling of an Endocrinologic and Metabolic Drugs Advisory Committee meeting on September 16, 2010, for the review of the lorcaserin New Drug Application. The shares are trading up pre market on [...]